Melatonin prolonged-release · Circadin

Unknown / undisclosed

Approvedregulatory verdict

Evidence outlook

Approved: monotherapy for the short-term treatment of primary insomnia characterised by poor... (EU)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
EU
  • Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Product first approved 2007Outside this platform's coverageEMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT01906866 · Neurim Pharmaceuticals Ltd.
2013-10 – 2018-03-27 · Sleep Disorders
What this study did
NCT00397189 · Neurim Pharmaceuticals Ltd.
2006-10 – 2009-04 · Primary Insomnia
What this study did
Phase 2 (5)
Other / comorbidity
NCT02789592 · Seoul National University Hospital
2016-07 – 2019-12 · REM Sleep Behavior Disorder, Parkinson Disease
What this study did
NCT00940589 · Neurim Pharmaceuticals Ltd.
2009-09 – 2013-05 · Alzheimer's Disease, Sleep Disorder
What this study did
NCT00972075 · Neurim Pharmaceuticals Ltd.
2006-02 – 2007-10 · Non-24 Hour Sleep-Wake Disorder, Blindness
What this study did
NCT00816673 · Neurim Pharmaceuticals Ltd.
1996-09 – 1997-09 · Primary Insomnia
What this study did
NCT00869128 · Neurim Pharmaceuticals Ltd.
1995-11 – 1997-03 · Diabetes Mellitus, Type 2, Insomnia
What this study did
Phase 1 (2)
Other / comorbidity
NCT01903681 · Neurim Pharmaceuticals Ltd.
2013-03 – 2014-04 · Sleep Problems
What this study did
NCT01741389 · University of Oslo
2012-12 – 2014-03 · Spinal Cord Injured, Tetraplegia
What this study did
Phase 4 (7)
Other / comorbidity
NCT03438526 · University Hospital, Basel, Switzerland
2022-01-03 – 2027-12 · Hypoactive Delirium
What this study did
NCT07737665 · Mahidol University
2025-04-01 – 2027-04-30 · IBD (Inflammatory Bowel Disease)
What this study did
NCT07034560 · Thammasat University
2024-11-12 – 2025-11-06 · Melasma, Treatment Outcome, Recurrence
What this study did
NCT03258294 · KIMJisun
2016-01-13 – 2018-12-30 · Parkinson's Disease
What this study did
NCT02836743 · Seoul National University Hospital
2016-01 – 2017-12-31 · REM Sleep Behavior Disorder
What this study did
NCT02768077 · Kuhnil Pharmaceutical Co., Ltd.
2016-01 – 2017-02 · Parkinson's Disease
What this study did
NCT01280734 · Neurim Pharmaceuticals Ltd.
2011-01 – 2011-05 · Postural Instability
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06489327 · Al-Azhar University
2026-07-12 – 2026-12-15 · Preoperative Anxiety
What this study did

Competitive landscape

Other Melatonin receptor (MT1/MT2) drugs

tasimelteon. Compare all 2 Melatonin receptor (MT1/MT2) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Melatonin Prolonged-Release (Circadin): this drugPhase 3—Melatonin receptor (MT1/MT2)Reliable signal
NCT01906866: Total Sleep Time (TST) (13 weeks): Circadin 2/5/10 mg 51.03 minutes (95% CI 30.3 to 71.76) vs Placebo 18.71 minutes (95% CI -2.73 to 40.15)
Tasimelteon (Hetlioz)
Approved(overall)
Small moleculeMelatonin receptor (MT1/MT2)Partial signal
NCT01430754: RESET randomized withdrawal: maintenance of entrainment, continued tasimelteon vs withdrawal to placebo: 9/10 (90%) vs 2/10 (20%), difference 70% (95% CI 26.4 to 100.0), p=0.0026 (Lockley et al., Lancet 2015).

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Circadin (Melatonin prolonged-release) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Early phase / not applicablePreoperative AnxietyRecruiting
Est. primary completion 2026-12-15 · NCT06489327 · CT.gov ↗
What to watch
2027 (2)
April 2027 (1)
Phase 4IBD (Inflammatory Bowel Disease)Recruiting
Est. primary completion 2027-04-01 · NCT07737665 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Hypoactive DeliriumRecruiting
Est. primary completion 2027-12 · NCT03438526 · CT.gov ↗
What to watch

See the full readout calendar ↗